An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease

An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease

Background: Alzheimer’s disease (AD) is a progressive neurodegeneration and is the most prevalent form of dementia. Intervention at an early stage is imperative. Although three acetylcholinesterase inhibitors (AChEIs) are currently approved for the treatment of mild AD, they are not sufficiently eff...

Full description

Bibliographic Details
Main Authors: Mosaburo Kainuma, Shinji Ouma, Shinobu Kawakatsu, Osamu Iritani, Ken-Ichiro Yamashita, Tomoyuki Ohara, Shigeki Hirano, Shiro Suda, Tadanori Hamano, Sotaro Hieda, Masaaki Yasui, Aoi Yoshiiwa, Seiji Shiota, Masaya Hironishi, Kenji Wada-Isoe, Daiki Sasabayashi, Sho Yamasaki, Masayuki Murata, Kouta Funakoshi, Kouji Hayashi, Norimichi Shirafuji, Hirohito Sasaki, Yoshinori Kajimoto, Yukiko Mori, Michio Suzuki, Hidefumi Ito, Kenjiro Ono, Yoshio Tsuboi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pharmacology
Subjects:
Alzheimer’s disease
hachimijiogan
ADAS‐Jcog
Kampo medicine
cognitive dysfunction
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.991982/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.991982/full

Similar Items